[SHINSA]Considerations for clinical development of intravenous formulations containing the same active ingredient as oral products for patients who are temporarily unable to receive oral administration in epilepsy treatment （Early consideration） posted
Early Consideration is reference information and point of view at that time for promoting the practi...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Early Consideration is reference information and point of view at that time for promoting the practi...
Source route
Continue on pmda.go.jp
Leave the platform to read the original full article on the publisher site.
Source: PMDA Japan
Scope: Regulatory
Related coverage
More related coverage
Decision: Advertising investigations: March 2026
Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines...
Kennedy expands ACIP function, membership criteria
Amending his previous two-year-renewal of the standard charter for the U.S. CDC’s Advisory Committee...
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026
PRAC agrees on communication to healthcare professionals about cases of severe liver injury with epi...
WHO releases US$800,000 from its Contingency Fund for Emergencies for Iran health response
10 April 2026, Cairo, Egypt – The World Health Organization (WHO) has released US$800,000 from its C...